Headquarters: Copenhagen, Denmark
CEO: Dr. Bo Rode Hansen
SEK as of April 1, 2022
|Company||Market Cap (USD)|
|Novo Nordisk||$257.24 B|
|CSL Limited||$89.69 B|
|Regeneron Pharmaceuticals, Inc.||$74.91 B|
|Moderna, Inc.||$70.81 B|
|Vertex Pharmaceuticals Incorporated||$67.49 B|
Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.
Scandion Oncology A/S has the following listings and related stock indices.
Stock: OMX: SCOL